TFE3 (Transcription factor E3) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a fusion partner, and the evidence so far is association rather than a proven role. Tied to Renal cell carcinoma, Sarcomas, Colorectal cancer and 1 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Transcription factor that acts as a master regulator of lysosomal biogenesis and immune response. Specifically recognises and binds E-box sequences (5'-CANNTG-3'); efficient DNA-binding requires dimerisation with itself or with another MiT/TFE family member such as TFEB or MITF. Involved in the cellular response to amino acid availability by acting downstream of MTOR: in the presence of nutrients, TFE3 phosphorylation by MTOR promotes its inactivation. Upon starvation or lysosomal stress, inhibition of MTOR induces TFE3 dephosphorylation, resulting in transcription factor activity. Specifically recognises and binds the CLEAR-box sequence (5'-GTCACGTGAC-3') present in the regulatory region of many lysosomal genes, leading to activate their expression, thereby playing a central role in expression of lysosomal genes. Maintains the pluripotent state of embryonic stem cells by promoting the expression of genes such as ESRRB; mTOR-dependent TFE3 cytosolic retention and inactivation promotes exit from pluripotency. Location: Cytoplasm, cytosol; Nucleus; Lysosome membrane (UniProt). Locus Xp11.23 (HGNC).
- Renal cell carcinoma: Open Targets association 0.66 with renal cell carcinoma (MONDO_0005086)
- Sarcomas: Open Targets association 0.57 with sarcoma (MONDO_0005089)
- Colorectal cancer: Open Targets association 0.50 with colorectal cancer (MONDO_0005575)
- Melanoma: Open Targets association 0.52 with melanoma (MONDO_0005105)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"TFE3" OR ABSTRACT:"TFE3" OR TITLE:"transcription factor binding to IGHM enhancer 3" OR ABSTRACT:"transcription factor binding to IGHM enhancer 3" OR TITLE:"Transcription factor E3" OR ABSTRACT:"Transcription factor E3" OR TITLE:"bHLHe33" OR ABSTRACT:"bHLHe33") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TFE3, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/tfe3.json. Licence CC BY-NC 4.0.